MYBANK
8.10.2019 08:37:04 CEST | Business Wire | Press release
MYbank, a leading online private commercial bank in China and an Ant Financial brand that focuses on SME (small and mid-size enterprise) financing, was yesterday named a PLATINUM winner of the Global SME Bank of the Year award category at the Global SME Finance Forum Awards for leveraging innovative digital technology to make finance accessible for tens of millions of SMEs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005902/en/
In 2015, MYbank pioneered the “310 model” for SMEs, which has enabled financial institutions in China to leverage proprietary risk management technologies so they can provide collateral-free business loans to SMEs. Not only has it enabled access to capital for SMEs, but they can apply for a loan simply by using their mobile phone, highlighting the ease and convenience of the model. Furthermore, as the name suggests, 3-1-0 lending enables borrowers to complete their online loan applications in three minutes, obtain approval in one second and with zero human intervention.
“We are very pleased to receive the recognition from IFC and the SME Finance Forum,” commented Simon HU, Chairman of MYbank, “In the age of the digital economy, digital finance can and should be used for the good of society. Our vision is to leverage digital technology and enable our financial partners to use the ‘310’ model to empower traditional unbanked and underbanked SMEs such as roadside vendors, mom-and-pop stores, and small business operators who contribute significantly to job creation and the growth of the real economy.”
On June 21, 2018, MYbank announced Star Plan which aimed to use technology to enable 1,000 financial institution partners to provide more cost-effective financing services to 30 million SMEs in China within a three-year period. As of September 2019, the 310 model has enabled MYbank and its over 400 financial institution partners to serve at least 20 million SMEs. Leveraging proprietary risk management technologies, MYbank helps keep the non-performing loan (NPL) ratio for the SME business loans offered through the 310 model at around 1%. As of June 2019, the size of each loan provided by MYbank was around RMB 10,000 (USD 1,400), reflecting the specific needs of SMEs, many of whom are roadside vendors, mom-and-pop shops and individual business operators with no more than five employees.
Simon HU added, “As the Star Plan progresses, we look forward to increasing the inclusivity of financial services for SMEs by sharing our technologies with more financial institution partners in China and beyond.”
Organized by IFC, a member of the World Bank Group, and the SME Finance Forum and endorsed by the G20’s Global Partnership for Financial Inclusion (GPFI), the Global SME Finance Awards celebrate the outstanding achievements of financial institutions and fintech companies in delivering exceptional products and services to their SME clients.
Matthew Gamser, CEO of the SME Finance Forum said: “We hope the winners of the Global SME Finance Awards will inspire SME financiers all over the world to learn from their good practices. The Awards provide the winners an opportunity to showcase good practices on the global stage and foster learning amongst their peers.”
This year’s award winners were selected from a competitive pool of 144 applicants. A panel of independent judges chose the winners based on their Reach, Uniqueness and Innovation, Effectiveness and Impact, and Dynamism and Scalability.
About the SME Finance Forum
The SME Finance Forum works to expand access to finance for small and medium businesses. The Forum operates a global membership network that brings together financial institutions, technology companies, and development finance institutions to share knowledge, spur innovation, and promote the growth of SMEs. Established in 2012 by the G20 Global Partnership for Financial Inclusion, the SME Finance Forum is managed by IFC. For more information, visit http://www.smefinanceforum.org
About MYbank
With a focus on serving SMEs and farmers, MYbank was established on June 25th, 2015 and was among the first batch of pilot private commercial banks in China. It was also the first bank in China to establish its core banking system entirely on the cloud without any physical branches. As one of the brands under Ant Financial Services Group, MYbank leverages Alipay’s AI, computing and risk management technologies to improve customer service and increase efficiency. MYbank’s efficient operating model enables its partner financial institutions to reduce costs.
Using a comprehensive AI-powered risk management system, which comprises of over 100 predicative models, 3,000 risk profiles and more than 100,000 metrics, MYbank calculates an appropriate line of credit for SMEs that minimizes the risk of excessive lending. As a result, the non-performing loan (NPL) ratio for MYbank’s SME business loans has consistently been at around 1%. As of end of 2018, the average NPL for SME loans in China was 3.16%, according to the People’s Bank of China .
For more details of the Star Plan, please refer to our official website: MYbank launches Star Plan to support 1,000 financial institutions to serve 30 million SMEs in the next three years
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom